Median Technologies Investors

16 investors on Angel Roster list Median Technologies in their portfolio. Most are venture capital firms and private equity firms, the most common stage is Series B and the largest groups are based in the United States, the United Kingdom and Canada.

Investors are matched on the company name in their portfolio, so companies that share the name Median Technologies can appear together.

Investors listed
16
With verified email
44%
Most common stage
Series B
Top location
United States

Updated October 13, 2026 · How we compile this data

Top 16 Median Technologies investors

The most complete profiles first. Showing 16 of 16.

  • Annie MitsakVerified

    Venture Capital, Investor · United States

    SeedHealth CareGeneticsWomen FoundedLife Science

    Portfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more

    Verified email available

  • Ken HaasVerified

    Venture Capital, Advisor, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • andrew sinclairVerified

    Venture Capital, Private Equity Firm, Investor · United Kingdom

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • AnneVerified

    Venture Capital · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more

    Verified email available

  • Paulina HillVerified

    Venture Capital · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more

    Verified email available

  • Shelley ChuVerified

    Venture Capital · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Tim HainesVerified

    Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Bali Muralidhar

    Venture Capital, Private Equity Firm, Investor · United Kingdom

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 69 more

    Contact details available

  • Brian Gallagher, Jr.

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Aileron Therapeutics, Amarin and 67 more

    Contact details available

  • Francesco Draetta

    Venture Capital, Investor · United States

    SeedHealth CareGeneticsWomen FoundedLife Science

    Portfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more

    Contact details available

  • Katie Kerfoot

    Venture Capital, Investor · United States

    SeedHealth CareGeneticsWomen FoundedLife Science

    Portfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more

    Contact details available

  • Kurt von Emster

    Venture Capital, Private Equity Firm, Investor · United States

    Series BHealth CareWomen FoundedInvestment ManagementLife Science

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Michelle Doig

    Venture Capital, Investor · Canada

    SeedHealth CareGeneticsWomen FoundedLife Science

    Portfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more

    Contact details available

  • Vin Miles

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • John Heard

    Venture Capital, Private Equity Firm · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Sarah Shackelton

    Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

By investment stage

By location

Related industries

Most-backed portfolio companies

Frequently asked questions

How many Median Technologies investors are on Angel Roster?

Angel Roster lists 16 Median Technologies investors. 7 of them (44%) include a verified email address.

What types of investors are they?

The most common investor types are Venture Capital Firms (16), Private Equity Firms (4) and Advisor Investors (1). An investor can have more than one type, for example an angel who is also a venture partner.

Which stages do Median Technologies investors invest in?

Among those that list a stage, the most common are Series B (6) and Seed (4).

Where are Median Technologies investors based?

Most are based in the United States (10), the United Kingdom (5) and Canada (1).

Which companies have Median Technologies investors backed?

The most-backed portfolio companies among them are Paratek Pharmaceuticals (16), Spruce Biosciences (16), IFM Therapeutics (16), Dicerna Pharmaceuticals (16) and Oxagen (16).

How do I contact Median Technologies investors?

Create a free Angel Roster account to search and filter all 16, then unlock verified emails and LinkedIn profiles on a paid plan. Every plan starts with a 3-day free trial.